New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Study shows KSM-66 Ashwaganda aids stress management

Study shows KSM-66 Ashwaganda aids stress management
Findings show KSM-66 significantly reduced stress in four measures, including a 28 percent reduction in cortisol levels over baseline.   

A study published in the current issue of Indian Journal of Psychological Medicine featuring KSM-66 Ashwagandha demonstrated a significant reduction in cortisol levels and in psychometric measures of stress, both in absolute terms and relative to the placebo group. The study concludes that KSM-66 Ashwagandha can help improve an individual's resistance to stress and can enhance quality of life.

The study used an extensive battery of psychometric scales assessing various manifestations of stress and its impact on an individual. KSM-66 Ashwagandha was shown to improve sleep quality, productivity and the extent of mental calmness and relaxation.

"These results validate the benefits of KSM-66 Ashwagandha for healthy stress management," said Kartikeya Baldwa, Director for Ixoreal Biomed. "This study examined how KSM-66 functions as an adaptogen assisting the body in producing a normalizing effect for reducing stress and anxiety. The study used established stress assessment scales and serum cortisol levels as the focal measures. The group taking KSM-66 Ashwagandha supplements experienced a significant reduction in stress over 60 days when compared against a placebo group."

The principal investigator who conducted the study, Dr. K. Chandrasekhar, is a reputed and distinguished physician. He is one of India’s leading psychiatrists and was recently the elected president of the premier professional body of psychiatry physicians in India. The study, conducted at Asha Hospital in Hyderabad, was a prospective, double blind, randomized and placebo-controlled trial conducted with 64 individuals with a history of chronic stress. These adults were otherwise normal and healthy, and not of pathological populations; therefore, the results of this study may likely extend to the larger general population of adults. 

Participants were evaluated on measures that included serum cortisol levels and well established stress assessment scales like the Perceived Stress Scale (PSS), the General Health Questionnaire-28 (GHQ-28) and the Depression Anxiety Stress Scale (DASS). The results showed that KSM-66 significantly reduced stress on all measures. The KSM-66 group demonstrated a reduction of 27.9 percent in serum cortisol level relative to the baseline.In terms of the GHQ-28 measure of stress, there was a 72.3 percent reduction in stress from baseline. In terms of the DASS measure, there was a 71.6 percent reduction and in terms of the PSS measure, there was a 44 percent reduction in stress.

KSM-66 Ashwagandha has the most extensive set of clinical trials of ashwagandha extracts available on the market today. Including this recently published study, there are five human clinical studies using KSM-Ashwagandha and two animal studies. Through these studies, KSM-66 Ashwagandha has been clinically documented to (i) reduce stress and anxiety, (ii) enhance memory and cognition, (iii) increase endurance and strength and (iv) improve sexual function health.

Mr. Baldwa adds, “Ixoreal Biomed has an expansive science mission. We are committed to continued investment in cutting-edge research and even more clinical trials so that the body of scientific evidence behind KSM-66 Ashwagandha continues to be unparalleled.”


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.